Pages that link to "Q53522491"
Jump to navigation
Jump to search
The following pages link to Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. (Q53522491):
Displaying 50 items.
- Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy (Q24796034) (← links)
- Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy (Q26801188) (← links)
- Quality of life issues in men undergoing androgen deprivation therapy: a review (Q27002887) (← links)
- Psychological adjustment of men with prostate cancer: a review of the literature (Q30479039) (← links)
- The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397). (Q31083661) (← links)
- Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer (Q33786586) (← links)
- Effect of sex and gender on psychosocial aspects of prostate and breast cancer (Q33807805) (← links)
- Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer (Q34000991) (← links)
- Management of complications of androgen deprivation therapy in the older man. (Q34782101) (← links)
- Cognitive effects of hormone therapy in men with prostate cancer: a review (Q35098762) (← links)
- Quality of life after treatment for prostate cancer (Q35131043) (← links)
- Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer (Q35433102) (← links)
- Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer (Q35441262) (← links)
- Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. (Q35602667) (← links)
- Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer (Q35689824) (← links)
- Complications of androgen deprivation therapy in men with prostate cancer (Q35739073) (← links)
- Complications of androgen-deprivation therapy in men with prostate cancer (Q36115631) (← links)
- Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer (Q36212442) (← links)
- The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study (Q36238011) (← links)
- Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer (Q36432836) (← links)
- Primary hormone therapy for locally advanced prostate cancer (Q36456160) (← links)
- Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer (Q36474222) (← links)
- Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. (Q36723162) (← links)
- Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial (Q36841565) (← links)
- Group-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol. (Q37063622) (← links)
- Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. (Q37103095) (← links)
- Prostate cancer: psychosocial implications and management (Q37236443) (← links)
- Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. (Q37472522) (← links)
- Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study (Q37523203) (← links)
- The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. (Q37678989) (← links)
- The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer (Q37708169) (← links)
- The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. (Q38086022) (← links)
- Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. (Q38156703) (← links)
- High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer (Q38352436) (← links)
- The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. (Q38817011) (← links)
- Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. (Q41728305) (← links)
- Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy (Q42644850) (← links)
- Sexuality and exercise in men undergoing androgen deprivation therapy for prostate cancer. (Q43639151) (← links)
- Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer (Q44803546) (← links)
- Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer. (Q46001813) (← links)
- Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. (Q46008021) (← links)
- Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life (Q46937617) (← links)
- Biopsychosocial impact of prostate cancer and androgen-deprivation therapy. (Q47550592) (← links)
- A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer (Q48039850) (← links)
- Risk factors: increased risk of suicide after prostate cancer diagnosis (Q49136017) (← links)
- Kamikihito improves cancer-related fatigue by restoring balance between the sympathetic and parasympathetic nervous systems. (Q55166267) (← links)
- Increased risk of suicide in New South Wales men with prostate cancer: Analysis of linked population-wide data. (Q55239964) (← links)
- Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT (Q57795886) (← links)
- The effects of testosterone replacement therapy on the prostate: a clinical perspective (Q64104589) (← links)
- Cancer-related symptoms, mental well-being, and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy (Q64108503) (← links)